Aims/hypothesis A new differentiation pathway for CD4 −
Introduction
Type 1 diabetes is an autoimmune disease in which the host loses tolerance to self-antigens at a young age. Consequently, auto-aggressive T cells infiltrate the pancreas and, over time, selectively destroy the insulin-producing beta cells, leading to overt diabetes [1] . Although there are a variety of mechanisms involved, convincing evidence indicates that the regulatory T cells (Tregs) play a key role in the acquisition and maintenance of peripheral tolerance [2] . In the peripheral lymphoid tissue of normal mice and humans, only 1-5% of αβ T cell receptor (TCR) + T cells are CD4 −
CD8
− (double-negative [DN]) T cells, capable of downregulating the immune response [3] . Adoptive transfer of allo-or xeno-antigen-activated DN T cells can prolong donor-antigen-specific skin and heart graft survival in mouse models [4] [5] [6] . Moreover, peptide-activated antigenspecific transgenic DN T cells can prevent autoimmune type 1 diabetes development [7] . Most recently, the DNCD3 splenic T cells from young NOD mice were demonstrated to be able to induce long-lasting protection against diabetes transfer into NOD/SCID mice [8] .
We recently identified a new differentiation pathway by which a subset of proliferated CD4 + T cells converted to DN T cells after four to five rounds of antigen-triggered or homeostatic proliferation in vitro and in vivo. These converted DN T cells displayed a phenotype and immunosuppressive function unique from those of CD4 + CD25 + Tregs, naive CD4 + CD25 − T cells, and activated CD4 + T cells. Moreover, using this novel pathway, tens of millions of DN T cells can be rapidly produced [9] . In this study, we sought to further test the functional potential of the converted DN T cells in an autoimmune diabetic NOD mouse model. Specifically, the ability of converted DN T cells to prevent and ameliorate autoimmune diabetes in NOD mice was investigated. Furthermore, on the basis of observations that rapamycin can selectively expand murine and human CD4 + CD25 + forkhead box P3 (Foxp3) + Tregs and concurrently inhibit effector T cell (Teff) expansion [10-12], we also report on the use of converted antigen-specific DN T cells in combination with rapamycin for the suppression of alloimmune response in vivo and the promotion of islet allograft survival in NOD recipients.
Methods
Animals Male B6D2F1(H2
), C57BL/6 (H2 b ), and DBA/2 (H-2 d ) and female NOD (H-2 g ), NOD/SCID and NOD.Cg-Tg (NOD.BDC2.5) mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA) and maintained in pathogen-free facilities at the University of Pittsburgh. The Institutional Animal Care and Use Committee at the University of Pittsburgh approved all animal procedures.
Conversion of NOD CD4
− CD8 − DN T cells in vitro CD4 + T cells were isolated from spleens and lymph nodes of NOD mice using a T cell enrichment column (R&D Systems, Minneapolis, MN, USA) and this was followed by Ter119-, B220-, CD8-, CD11b-, TCRγδ-and NK1.1-positive cell depletion. Mature dendritic cells (mDCs) were harvested from lipopolysaccharide-stimulated bone marrow cells of NOD mice, and separated by CD86-positive selection. CD4 + T cells were cultured in 96 well roundbottom plates in complete medium (RPMI 1640 supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin, 10% [vol./vol.] FBS, 2 mmol/l L-glutamine and 50 μmol/l 2-mercaptoethanol) containing recombinant mouse (rm) IL-15 (100 ng/ml; Prospec-Tany, Rehovot, Israel), and stimulated with NOD mDCs at a ratio of 100,000 T cells to 25,000 DCs for up to 6 days, in the presence of GAD65 peptides or control peptides (0.1 μg/ml; GenScript Scotch Plans, NJ, USA). GAD65 peptides that encode the confined region of GAD65 included peptide 247-266 (NMYAMMIARFKMFPEVKEKG), peptide 509-528 (IPPSLRTLEDNEERMSRLSK), peptide 524-543 (SRLSKVAPVIKARMMEYGTT) and peptide 539-558 (EYGTTMVSYQPLGDKVNFFR). Control peptides that come from a non-confined region of GAD65 and do not trigger autoimmune responses included peptide 157-176 (EEILMHCQTTLKYAIKTGHP). CD4
−

CD8
− DN fractions were isolated from mixed lymphocyte reaction (MLR) and sorted using a FACS (Aria; BD Biosciences, San Diego, CA, USA).
In vitro re-stimulation and cytokine assays DN T cells sorted from MLR cultures were re-cultured in 96 well plates (2×10 5 /well), and stimulated with anti-CD3 and anti-CD28 monoclonal antibodies (mAbs, each 2 μg/ml; BD Pharmingen, San Diego, CA, USA) for 1 or 2 days. The cytokine secretion in cell culture supernatant fractions was measured using a mouse ELISA kit (R&D Systems).
In vitro suppression assays CD3 + T cells (1×10 5 /well) from NOD.BDC2.5 mice were co-cultured in anti-CD3 mAb-coated 96 well plates with mitomycin C-treated NOD splenocytes (1×10 5 /well) for 4 days. Anti-CD3 mAb was used at 1 μg/ml; mitomycin C was from Sigma-Aldrich (St Louis, MO, USA In vivo suppression assays Carboxyfluorescein succinimidyl ester (CFSE)-labelled C57BL/6 CD3 + T cells (20×10 6 ) were adoptively transferred into B6D2F1 recipients by tail-vein injection with or without 5×10 6 DN T cells (purified from MLR of DBA/2 mDCs and C57BL/6 Teffs). Recipients were treated with or without rapamycin (0.6 mg/kg; Sigma-Aldrich). Spleens were harvested 3 days after adoptive transfer, and single-cell suspensions were prepared and stained with annexin V (BD Pharmingen) for flow cytometry.
Adoptive transfer and islet transplantation DN T cells (5× 10 5 ) obtained from in vitro MLR with or without GAD65 peptides, as described, in combination with 5×10 5 T cells from diabetic NOD mice were transferred to NOD/SCID mice by tail-vein injection. Additionally, DN T cells (2×10 6 ) were transferred to 5-week-old female NOD mice. Mice were monitored for the development of diabetes by measuring blood glucose levels twice weekly. In the event of new-onset diabetes, DN T cells (4×10 6 ) were transferred to the new-onset diabetic NOD mice, and blood glucose levels were followed up every other day following adoptive transfer. In an islet allograft model, GAD65 peptide-primed DN T cells (5×10 6 ) were injected into new-onset diabetic NOD mice. On the same day, approximately 800 DBA/2 islets were transplanted under the kidney capsule of NOD mice. Recipients were treated i.p. with or without rapamycin (0.6 mg/kg, daily for 14 days). Allograft function was assessed by monitoring blood glucose levels. Diabetes or islet allograft rejection was defined as blood glucose levels of >16.7 mmol/l in two consecutive measurements.
Flow cytometric analysis Cultured cells were harvested at various time points and analysed for the proliferation and expression of various cell surface markers. Cells were acquired on an LSRII flow cytometer (BD Biosciences) and data analysis was performed using FlowJo software (Tree star, Ashland, OR, USA).
Real-time PCR Total RNA was extracted from cells using an RNeasy mini-kit (Qiagen, Valencia, CA, USA) and reverse transcribed to cDNA using SuperScript III RT-kit (Invitrogen, Carlsbad, CA, USA). Specific mRNA levels were quantified by real-time PCR using the ABI 7500 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). Genespecific primers and probes for Il2, Il4, Il17 (also known as Il17a), Foxp3, Ifnγ (also known as Ifng), Fasl, granzyme B (GZMB) and perforin (PRF) were purchased from Applied Biosystems. Data are expressed using the C t method and normalised to the housekeeping gene Gpdh.
Statistical analysis Analyses for statistically significant differences were performed using the Student's t test and one-way ANOVA test. The influence of different treatments on islet allograft survival was analysed using a logrank test; p<0.05 was considered significant.
Results
DN T cells can be converted from NOD CD4
+ T cells in syngeneic MLR To explore the potential application of DN T cells converted from the CD4 + T cells of a NOD host to block autoimmune diabetes in NOD mice, CFSE-labelled CD4 + T cells isolated from spleen and lymph nodes of female NOD mice were co-cultured with syngeneic bone marrow mDCs plus rmIL-15. After 6 days in vitro MLR, approximately 50% of NOD CD4 + T cells lost CD4 expression (Fig. 1a, b) . Consistent with our previous report, the converted DN T cells expressed a unique set of cell surface markers: Fig. 1c-j) . Additionally, compared with NOD CD4 + T cells, converted DN T cells expressed undetectable Foxp3, Il2 and Il4 mRNA levels, very low Il17 mRNA levels, but high Ifnγ, Fasl, GZMB and PRF levels ( Fig. 1k-m) . Upon re-stimulation with anti-CD3/CD28 mAb, IL-2 and IL-4 levels in the converted DN T cell culture supernatant fractions were significantly lower, while IFN-γ production was higher than that in the CD4 + T cells ( Fig. 1n-p ). In addition, the converted DN T cells maintained a stable CD4 − phenotype and low proliferation after re-stimulation, as previously reported by Zhang et al. [9] , consistent with anergic properties ascribed to DN T cells.
The addition of GAD65 peptides in the initial MLR enhances regulatory function of DN T cells As GAD65 is a putative self-antigen produced by beta cells and plays a critical role in the initial events in type 1 diabetes [13, 14], synthetic peptides derived from a GAD65 isoform were added in the initial MLR to induce beta cell-specific DN T cells. Histopathological changes were assessed in haematoxylin and eosin (H&E)-stained pancreas sections from adoptively transferred NOD/SCID recipients at week 5 after cell transfer. A massive mononuclear cell infiltration of the islets with loss of islet structure was observed in NOD/SCID recipients that received T cells from diabetic NOD donors (Fig. 3a) . In contrast, pancreas harvested from NOD/SCID recipients given DN T cells alone (either with or without GAD65 priming) (Fig. 3c, e ) or in combination with diabetogenic T cells (Fig. 3b, d ) showed normal islet structure without obvious mononuclear cell infiltration, suggesting that DN T cells converted from diabetogenic CD4 + T cells possess the ability to suppress diabetogenic T cells and prevent autoimmune disease in vivo.
Adoptive transfer of DN T cells can prevent diabetes development and reverse new-onset diabetes To explore the potential application of DN T cells in preventing type 1 diabetes, DN T cells (converted from CD4 + CD25
− T cells of NOD mice by co-culture with NOD mDCs, rmIL-15 and GAD65 peptide in MLR for 6 days) were adoptively transferred into 5-week-old prediabetic NOD female mice. The administration of single dose of 2×10 6 DN T cells resulted in a significant delay of diabetes onset from 11 weeks post adoptive transfer in the untreated group to 17 weeks post adoptive transfer in the DN treated group. At 25 weeks post adoptive transfer, 85% of the untreated NOD mice developed diabetes, whereas only 25% of the NOD mice given GAD65-primed DN T cells therapy became diabetic (Fig. 4a) . Reversing new-onset autoimmune diabetes in NOD mice is a more daunting challenge. Our results show that a single transfer of 4×10 6 DN T cells slightly, but significantly, postponed the progression of hyperglycaemia in new-onset diabetic NOD recipients. Blood glucose levels of mice treated with DN T cells were significantly lower than those of the control groups, but there was no reversal of hyperglycaemia. However, a single transfer of an equivalent amount of GAD65-primed DN T cells into new-onset diabetic NOD mice resulted in reversal of hyperglycaemia in all recipients within 12 days. Two recipients remained diabetes free over 3 months. The rest of the recipients showed transient reversal of autoimmune diabetes; blood glucose levels started to rise after 12 days of adoptive transfer (Fig. 4b) .
DN T cells act in conjunction with rapamycin to inhibit alloimmune response, promote T cell apoptosis and prolong islet allograft survival To examine the influence of DN T cells combined with rapamycin on the proliferation of alloreactive T cells in vivo, CFSE-labelled C57BL/6 CD3 + T cells were adoptively transferred into B6D2F1 recipients. Flow cytometry analysis revealed that both CD4 + and CD8 + T cells from C57BL/6 mice exhibited robust proliferation after 3 days of adoptive transfer in B6D2F1 recipients. DN T cell treatment alone did not significantly inhibit T cell proliferation. Administration of rapamycin at a dose of 0.6 mg/kg partially inhibited both CD4 + and CD8 + T cell proliferation, though greater inhibition of CD8 + T cell proliferation was observed. However, the combination of DN T cells and rapamycin exerted more potent suppression of both CD4 + and CD8 + T cell proliferation than that achieved with rapamycin alone (Fig. 5a-h) . Moreover, combined treatment of DN T cells with rapamycin significantly increased annexin V staining for both CD4 + and CD8 + T cells (Fig. 5i-p) , suggesting an enhanced apoptosis of alloreactive T cells in vivo. In order to evaluate the influence of DN T cells and rapamycin on allograft survival, MHC mismatched DBA/2 islet allografts were transplanted into diabetic NOD mice. As shown in Fig. 6 , untreated recipients rejected their grafts in a mean survival time (MST) of 6 days (n = 4). Administration of rapamycin or DN T cells alone did not significantly delay islet allograft rejection (MST, 8 day; n=5). In contrast, single transfer of 5×10 6 GAD65-primed converted DN T cells plus 14 day rapamycin treatment significantly prolonged islet allograft survival (MST, 40 days, p=0.002) and proved more effective in promoting engraftment than the two monotherapies (p<0.01).
Discussion
Tregs have emerged as being critically important for the control of autoimmunity and for the maintenance of allograft tolerance [15, 16] . As the elucidation of the immunoregulatory properties of CD4 − CD8 − DN T cells in T cell-mediated immune response, it has been anticipated that adoptive cell therapy using DN T cells could become an attractive treatment for autoimmune disease and transplant rejection [3, 4] . Nevertheless, the lack of precise markers, sufficient number and antigen specificity of DN T cells are major hurdles for their in vivo application. We have identified a new differentiation pathway in a normal mouse model for the conversion of mouse peripheral CD4 + T cells to DN regulatory T cells. These converted DN T cells were resistant to activation-induced cell death (AICD) and were highly potent in suppressing alloimmune responses both in vitro and in vivo in an antigen-specific manner [9] . In this study, we further demonstrated the conversion of CD4 + T cells isolated from NOD mice with the stimulation of syngeneic mDCs plus rmIL-15 in vitro. Fig. 1n -p, the IL-2 and IL-4 production was lower, while IFN-γ was higher in DN T cell culture supernatant fractions after re-stimulation in comparison with that of CD4 + T cells. This finding provides the feasibility of NOD CD4 + -converted DN T cells to be used in autoimmune diabetic NOD model and suggests that this cell population is uncommon to other Tregs subsets and cytotoxic features may contribute at least partially to their unique regulatory ability.
After 6 days MLR, approximately 50% of the proliferated T cells were identified as DN T cells by expressing
Studies have revealed that the beta cell antigen-specific Tregs are more potent in blocking autoimmune diabetes, even in a highly diabetes-prone Treg-deficient CD28KO NOD model [17] . GAD has come under the scrutiny of diabetes researchers because some of the earliest auto-antibodies found in prediabetic patients are GAD specific [18, 19] . There is also evidence that the presence of GAD protein in beta cells is strictly correlated with the development of diabetes in NOD mice and that GAD is the essential autoantigen to initiate the disease by activating GAD-specific T cells. Additionally, when transplanted into diabetic NOD , n=4) , with or without GAD65 priming (circles, n=4), remained diabetes free for more than 25 weeks post adoptive transfer mice, islet cells unable to produce GAD, but not normal islet cells, were spared from immune attack [20] . As the confined region of GAD65 that triggers initial autoimmune responses has been identified [13], we employed synthetic GAD65 peptides for the induction of beta cell antigen-specific DN T cells and hypothesised that DN T cells induced by syngeneic mDCs plus GAD65 peptide would possess beta cell antigen specificity and the ability to suppress autoimmunity. Indeed, the addition of GAD65 peptides in the MLR had a similar effect on the conversion rate, cell surface phenotype and gene expression profile of converted DN T cells (data not shown) as that without GAD65 peptide treatment. To test the regulatory function of converted DN T cells on beta cell antigen-specific T cell immune responses, we used NOD.BDC2.5 mice, which carry both rearranged Tcrα (also known as Tcra) and Tcrβ (also known as Tcrb) genes from the diabetogenic H2-Ag7 restricted BDC2.5 CD4 + T cell clone [21] . Our results show that the NOD CD4 + converted DN T cells significantly suppressed anti-CD3 and syngeneic antigen presenting cells (APCs) triggered NOD.BDC2.5 T cell proliferation, in which the DN T cells primed with GAD65 peptides exerted much more potent suppressive ability, demonstrating the effect of antigen-specific DN T cells on autoimmune response.
The functional potential of the converted DN T cells on autoimmune diabetes was further demonstrated in an adoptive transfer model in NOD/SCID recipients. The co-transfer of an equal number of DN T cells with diabetogenic NOD T cells resulted in a delay of diabetes onset in NOD/SCID recipients, and the GAD65-primed DN T cells further delayed autoimmune diabetes compared with the NOD T cells transfer group, accompanied by a marked decrease in pancreas mononuclear cell infiltration at 5 weeks after adoptive cell transfer. Furthermore, the adoptive transfer of a single dose of 2×10 6 DN T cells into 5-week-old NOD hosts resulted in the significant delay and reduced the incidence of diabetes onset. This finding supports the idea that the application of ex vivo CD4 + converted DN T cells is beneficial to prevent autoimmune diabetes in the NOD model and that peptide-activated antigen-specific DN T cells can exert a more potent effect in vivo. Thus, the inhibition of the homing, proliferation and effect function of isletdestructive T cells may at least in part underlie the delayed onset of autoimmune diabetes induced by converted DN T cells. We did not study the homing of DN T cells in this study because of the lack of a proper tracking marker. We have previously analysed the homing of the converted C57BL/6 DN T cells after their adoptive transfer to syngeneic Rag-1 knockout mice, which were then challenged with the DBA/2 skin allograft. We found that CD3 Although numerous treatments that prevent the development of diabetes and progression of the autoimmune 'invasive insulitis' in prediabetic NOD mice have been identified, far more challenging is the restoration of a euglycaemic state in mice with frank type 1 diabetes [22] . The infusion of islet-specific Tregs, which were isolated from NOD.BDC2.5 mice and were expanded with antigenpulsed DCs and IL-2 in vitro, was effective in inducing long-lasting reversal of hyperglycaemia in 50% of mice in which overt diabetes had developed [23] . In this study, we assessed the ability of converted DN T cells to treat newonset diabetic NOD recipients. A single transfer of 4×10 6 DN T cells significantly postponed the progression of hyperglycaemia, though there was no reversal of hyperglycaemia. However, a single transfer of the same number of GAD65-primed DN T cells resulted in reversal of hyperglycaemia in all recipients within 12 days. Two recipients remained diabetes free over 3 months. The rest of the recipients showed transient reversal of autoimmune diabetes: blood glucose levels started to rise after 12 days of adoptive transfer. These results suggest the favourable influence of antigen-specific DN T cells on the treatment of new-onset autoimmune diabetes. Therefore, our data show the promise of DN T cell-based therapy for improvement in autoimmune diabetes.
Islet transplantation offers hope for patients with type 1 diabetes, with physiologically regulated insulin release by islet allograft preventing diabetes-related complications. However, transplantation of islet allografts into spontaneously diabetic NOD hosts provides an even more daunting challenge because of the generalised defect in tolerance mechanisms and the presence of pre-activated cytopathic islet-specific autoimmune T cells [24, 25] . Rapamycin is a macrolide antibiotic with potent immunosuppressive and immunoregulatory properties. The mammalian target of rapamycin has an important role in modulating innate and adaptive immunity [26] . In this study, we have demonstrated that converted DN T cells and rapamycin act in concert in vivo to inhibit the proliferation and promote the apoptosis of both CD4 + and CD8 + T cells. This suggests potential interaction between DN T cells and rapamycinsensitive mammalian target of rapamycin signalling pathways in T cell-cycle progression. However, DN T cells by themselves do not have a significant effect on CD4 + or CD8 + T cell proliferation and apoptosis induction, which differed from the effects previously observed in vitro or in vivo [9, 27] . This discrepancy might be due to the complexity of alloimmune responses in vivo, which depend on the extent of immune stimulation and the sufficiency of DN T cell-mediated regulation. In an adoptive transfer model, the naive T cells from C57BL/6 mice encountered alloantigens of MHC-mismatched B6D2F1 recipients both by direct and indirect antigen-presentation pathways and resulted in a robust T cell activation and proliferation as shown in Fig. 5 . It is not a surprise that adoptive transfer of DN T cells alone did not have a significant effect on alloreactive CD4
+ and CD8 + T cell proliferation demonstrated by both CFSE-assisted assay and islet allograft survival, because the more rapid expansion of alloaggressive T cells overcomes the protective effects of DN regulatory T cells. In contrast, the effective immunosuppressive rapamycin therapy that significantly reduced the alloreactive CD4 + and CD8 + T cells allowed DN regulatory T cells to exert their suppressive effects. This is consistent with previous reports [28] [29] [30] . We further assessed whether combined DN T cells and rapamycin treatment can promote islet allograft engraftment in MHC-mismatched pancreatic islet allotransplantation in autoimmune NOD recipients. Indeed, the single-dose transfer of DN T cells plus 14 days of rapamycin administration achieved significant prolongation of islet allograft survival compared with any of the monotherapies, indicating the beneficial role of the DN T cell-based immunoregulatory strategy in NOD islet allograft engraftment. The concerted influence of these two components on autoimmune T cell activity and AICD may ensure effective control of anti-donor reactivity and promote allograft survival. However, further tailoring the dose and/or frequency of GAD65-primed DN T cells in concomitant regimens will be required for optimal therapeutic effect in type 1 diabetes and islet allotransplantation. In short, this study demonstrates that beta cell antigenspecific DN T cells can be induced from prediabetic NOD CD4 + T cells in vitro, efficiently prevent the onset and progress of autoimmune diabetes in vivo, and also act in conjunction with rapamycin to promote islet allograft survival in NOD mouse models. The isolation of tens of millions of highly purified CD4 + T cells from the peripheral blood of a patient is within reach of current clinical technology. By stimulating highly purified CD4 + T cells with syngeneic or allogeneic bone marrow mDCs or APCs plus rmIL-2 and/or rIL-15, it is possible to convert sufficient antigen-specific DN T cells within a few days. Our results using DN T cells converted from prediabetic NOD CD4 + T cells in adoptive transfer and islet transplantation models shows a promising cell-based strategy for treatment of autoimmune diabetes and its feasibility in clinical application.
